Global X CleanTech vs Johnson & Johnson — how do they compare? Global X CleanTech trades at $58.94, while Johnson & Johnson trades at $252.82 (market cap $611.07B). The key difference: Johnson & Johnson pays a 2.11% dividend while Global X CleanTech pays none, and Johnson & Johnson is trading nearer its 52-week high, Global X CleanTech nearer its low. Which is the better fit depends on your goals.
| CTEC | JNJ | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $78.11 | $267.24 |
52-Week Low | $39.45 | $155.17 |
Market Cap | — | $611.07B |
Volume | — | 6,156,228 |
Enterprise Value | — | $644.01B |
Dividend Yield | — | 2.11% |
Signals from Pluang's Aura AI — not financial advice
CTEC trades at $57.34, down 2.88% today amid bearish technical signals, with moving averages indicating selling pressure but oscillators showing potential oversold conditions. Key financial ratios including P/E, P/S, and ROE are unavailable, limiting fundamental clarity. The company has announced a future dividend of $0.07 per share payable in July 2026, though recent earnings and cash flow data are not provided.
The outlook remains cautious due to weak technical momentum and incomplete financial disclosure. Investment opportunity hinges on upcoming financial results revealing profitability and growth, while risks include persistent selling pressure and lack of current fundamental visibility. Investors await clearer earnings updates to assess valuation and business health.
Johnson & Johnson (JNJ) trades at $257.77, up 0.31% with a bullish technical signal and strong institutional support. The stock shows robust fundamentals with 2025 revenue of $94.19B, net income margin of 21.83%, and consistent earnings beats. Recent dividend declaration of $1.34 and positive analyst coverage with 52.5% buy ratings reinforce confidence. The current price sits near pivot point resistance at $258, with technical indicators showing bullish momentum from moving averages.
JNJ presents a compelling long-term investment with stable cash flows, strong profitability metrics, and defensive healthcare positioning. Upside potential exists toward the $281 consensus price target, though risks include rising debt-to-asset ratio (24.06% in 2025) and patent expiration headwinds. The stock's 60+ year dividend growth history provides income stability amid market volatility.
Trailing returns across standard periods
Latest headlines on both assets
CTEC invests in companies at the forefront of the clean technology industry. It focuses on disruptive innovations in renewable energy production, energy storage, smart grids, and energy efficiency, with top holdings like Enphase and First Solar.
Read more on CTEC →Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →